Anmeldung erfolgt in Kürze...
Details werden geladen...
BioNTech and Pfizer tout bispecifics data, and Pazdur sees silver lining at FDA
ASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.
Ähnliche Seiten
At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer
https://www.statnews.com/2026/05/29/asco-news-day-1-multiple-myeloma-bristol-lung-cancer-pfizer/A standing ovation for RevMed, and caution for Akeso | STAT
https://www.statnews.com/2026/05/31/asco-news-day-3-revmed-akeso-summit-lilly-kelonia/At ASCO, talk of barriers to cancer care, new treatments, and other big takeaways
https://www.statnews.com/2026/06/01/asco-news-day-4-merkel-cell-carcinoma-glp1s-grail/
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
https://www.finanznachrichten.de/nachrichten-2026-05/68638430-immatics-presents-data-on-ima401-magea4-8-bispecific-at-2026-asco-annual-meeting-with-simultaneous-publication-in-nature-medicine-supporting-developme-399.htmPharmalittle: We're reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and more | STAT
https://www.statnews.com/pharmalot/2026/05/29/pharmalittle-were-reading-about-replimune-drug-getting-third-try-at-fda-approval-a-pfizer-deal-in-china-and-more/